Share This

Public company info - CanSino Biologics Inc. - H Shares , 06185.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

CanSino Biologics Inc. - H Shares, 06185.HK - Company Profile
Chairman Xuefeng YU
Share Issued (share) 133,000,000
Par Currency Renminbi
Par Value 1.0
Industry Biotechnology
Corporate Profile Business Summary: CanSino’s mission is to develop, manufacture and commercialize high quality, innovative and affordable vaccines. Performance for the year: The Group did not generate any revenue for the year ended December 31, 2019. Business Review： CanSino’s mission is to develop, manufacture and commercialize high quality, innovative and affordable vaccines. The Group’s mission is being fulfilled by an accomplished team of founders and senior management – world-class scientists with a record of leading the development of innovative international vaccines at global pharmaceutical companies. Other management members are also vaccine industry veterans from leading multi-national and domestic biologics companies. The Group’s vaccine pipeline, which is strategically designed to address China’s vast and underserved market, can be summarized into three categories: (i) globally innovative vaccines to serve China’s unmet medical needs (such as Ad5-EBOV, the Group’s TB Booster candidate, the Group’s PBPV candidate and the Group’s Ad5-nCoV candidate); (ii) potential first-in-class vaccines in China developed to replace the current primary vaccines with higher-quality world-class vaccines (such as the Group’s DTcP vaccine candidates and MCV4 candidate); and (iii) potential best-in-class vaccines in China developed to compete with the imported products in the PRC market (such as the Group’s PCV13i candidate). The Group are developing 16 vaccine candidates for 13 disease areas. In addition to the Group’s three near-commercial assets covering meningococcal diseases and Ebola virus disease, the Group have seven vaccine candidates in clinical trial stage or CTA stage. The Group also have six pre-clinical vaccine candidates, including one combination vaccine candidate. To date, the Group have not commercialized any products, and the Group cannot guarantee that the Group will be able to successfully develop and commercialize the Group’s drug candidates. Prospects: According to China Insights Consultancy Limited, in terms of sales revenue, the total size of China’s vaccine market increased from RMB23.3 billion in 2014 to RMB33.6 billion in 2018, and is expected to reach RMB116.1 billion in 2030. The Group’s mission is to develop, manufacture and commercialize high quality, innovative and affordable vaccines. To accomplish that mission, the Group will continue to advance the Group’s near-commercial candidates towards the NDA approval and develop the Group’s clinical trial stage assets through the Group’s in-house research and development and medical/clinical teams. Also, the Group will continue to discover and develop new vaccine candidates through both in-house research and development and external collaborations. In order to support the Group’s continuous growth, the Group plan to establish and strengthen the Group’s commercialization infrastructure, and expand the Group’s marketing and commercialization team. The Group will continue to evaluate possible global collaborations and acquisitions of high-potential assets.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.